33 results about "Antigen variation" patented technology

The invention discloses a method for predicting flu antigen through a model and an application thereof. The method comprises the following steps: extracting 12 features affecting the flu antigen, wherein the 12 features include mutation numbers of five antigenic determinant amino acid, five physical and chemical properties of HA protein amino acid, factor affecting receptor, and number of glycosylated site, the five physical and chemical properties of amino acid include hydrophobicity, volume change, electriferous property, polarity and integrable surface area; and making statistics on the 12 features of 3681 virus pairs similar to known antigen and 1720 virus pairs variant from antigen, thereby establishing a prediction model on antigen relation. On the basis of sequence, the method can present the antigen relation among viruses, and thus having the advantages of simpleness, convenience and high sensitivity. The process of antigen evolution can be visually displayed through the network. The invention is used for revealing flu spreading rules, screening vaccine candidate strains and the like.

The invention provides a synthetic peptide vaccine for treating porcine reproductive and respiratory syndrome and a preparation method thereof, in particular relates to polypeptide of the synthetic peptide vaccine for treating the porcine reproductive and respiratory syndrome and a vaccine which contains the polypeptide and a method for preparing the polypeptide and the vaccine. The amino acid sequence of the polypeptide is an amino acid sequence shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 or SEQ ID No.4. The vaccine prepared from the polypeptide can effectively cope with the antigenic variation of a porcine reproductive and respiratory syndrome virus, ensures biological safety, is easy for large-scale synthesis and has good application prospect.

The invention provides an adaption method of influenza virus vaccine strains on Vero cells. The influenza virus vaccine strains are rapidly adapted on the Vero cells; and various effective virus adaption methods are established, so that influenza virus seeds can be adapted on the Vero cells, and virus progenies used as vaccines are produced under the condition of minimizing virus surface antigen variation caused by virus adaptation selection. The hemagglutination titer of the virus seeds prepared by vaccine strains adapted by the method is more than or equal to 160, and meets the requirementsof three parts of the Chinese pharmacopoeia, 2010 edition.

The present invention relates to a novel MDCK-derived cell line capable of being suspension-cultured in a protein-free medium and a method for proliferating a virus using the MDCK-derived cell line to produce a vaccine. The novel MDCK-derived cell line exhibits high and uniform productivity for various viruses, while causing less viral antigenic variations with low tumorigenicity, and thus can be useful in producing viruses used for vaccines.

The invention provides polypeptide used for preparing O type peptide vaccine of cattle foot-and-mouth disease. The polypeptide comprises an amino acid sequence presented by SEQ ID NO.1 and the peptide vaccine containing the polypeptide. The O type synthetic peptide vaccine of cattle foot-and-mouth disease provided by the invention has excellent immune efficacy, and cannot cause the problems of fever, swelling and the like existing in traditional vaccines, so that the vaccine can effectively respond to antigenic variation of current foot-and-mouth disease virus, prevents biosecurity problems, is easy to synthesize in a large scale, and has an excellent application prospect. The invention further provides preparation methods and pharmaceutical applications of the polypeptide and the peptide vaccine.

The invention provides antigen polypeptide, a polypeptide composition and a vaccine for preparing a porcine circovirus synthetic peptide vaccine. The antigen polypeptide is polypeptide shown in the sequence 1, sequence 2, sequence 3 or sequence 4. The synthetic peptide vaccine comprises polypeptide or a polypeptide composition. The provided porcine circovirus synthetic peptide vaccine is excellent in immune effect and doesn't cause problems of fever and redness existing in conventional vaccine. The vaccine can effectively overcome the problems including antigenic variation of porcine circovirus and absence of biological safety, is easy for massive synthesis, and has bright application prospects. The invention further provides a preparation method of polypeptide and a polypeptide vaccine and a pharmaceutical application thereof.

The invention discloses an antigen polypeptide, a polypeptide composition and a vaccine for preparing a bovine foot and mouth disease A-type polypeptide vaccine. The polypeptide composition comprises a polypeptide obtained by connecting the polypeptide fragment shown in sequence 1 with the polypeptide fragment shown in sequence 5. The vaccine provided by the invention comprises the polypeptide composition. The bovine foot and mouth disease A type polypeptide vaccine provided by the invention has good immune potency, so that the problems of fever, red and swollen caused by the traditional vaccine cannot be triggered. The vaccine provided by the invention can effectively response the antigenic variation of the current foot and mouth disease virus, is free of biological safety, easy for large-scale synthesize and has a good application future. The invention additionally discloses a preparation method of the polypeptide and the polypeptide vaccine and a pharmaceutical application thereof.

The invention relates to the field of animal virology, and provides separation, identification and application of an avian H9N2 subtype avian influenza virus strain. The H9N2 subtype avian influenza virus strain is preserved in China General Microbiological Culture Collection Center on July 02, 2019 with the preservation number of CGMCC No. 18172. The antigen variation condition of the separated strain is explained from the molecular level; the virus strain is inactivated with formaldehyde, and then is processed together with a 605 adjuvant to prepare an inactivated vaccine, 21-day-old SPF chickens are immunized, the immune effect is evaluated through a serological method and an immune challenge method, it is proved that the strain is good in protection effect, and the strain can be used as an avian influenza H9N2 subtype vaccine candidate strain. The invention provides an idea for bird flu prevention and control, provides technical teaching for bird flu candidate strain screening, andhas great public health significance.

The invention provides a swine fever synthesized peptide vaccine and a preparation method thereof. The invention specifically relates to polypeptide used for synthesizing the swine fever synthesized peptide vaccine, a vaccine containing the polypeptide, and a preparation method thereof. The amino acid sequence of the polypeptide is represented by SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, or SEQ ID No.4. With the vaccine prepared from the polypeptide, antigen variations of swine fever viruses can be effectively coped with, and a bio-security problem is avoided. The polypeptide vaccine is suitable for large-scale synthesizing, and has a good application prospect.

The invention provides a synthetic peptide vaccine and particularly relates to polypeptide or a polypeptide polymer thereof used for the synthetic peptide vaccine for O type foot-and-mouth disease, the vaccine containing the polypeptide or the polypeptide polymer thereof and preparation methods of the polypeptide or the polypeptide polymer thereof and the vaccine, wherein the polypeptide has the amino acid sequence as indicated in SEQ ID No .2 .According to the synthetic peptide vaccine and the preparation method thereof, candidate peptide antigen is screened through a great number of animal tests, foot and mouth disease virus antigen sites are optimized according to the screening result, T cell epitope and B cell epitope are effectively combined, and the immune effect of the polypeptide antigen is enhanced .The synthetic peptide vaccine for O type foot-and-mouth disease can effectively cope with antigen variation of foot-and-mouth disease virus, biosecurity is good, large-scale synthesis can be conducted easily, and good application prospect is achieved.

The present invention provides a novel branched-chain sialose molecule represented by the following formula (I), which is capable of preventing type A from all humans and animals as a host-wide variation or antigenic variation against influenza virus Substances used for adsorbents such as pharmaceuticals infected with influenza virus and influenza B virus, and filters for virus removal. (In the formula, NeuAc represents N-acetylneuraminic acid in which the hydroxyl group, carboxyl group and amide group of the NeuAc may be chemically modified by halogen, alkyl group or acyl group in the same or different ways, Hex represents hexose, HexNAc represents acetylhexosamine , R is a matrix selected from hydrogen atoms, hydrocarbon chains, sugar chains, lipids, proteins, and synthetic polymers, and R may also have substituents. In addition, the combination of N-acetylneuraminic acid and hexose may be naturally occurring The ortho-glycosidic bond may be a chemically transformed bond such as S-glycosidic or Se-glycosidic bond.)

The invention discloses an epidemic prediction and early warning management system. The system comprises a data layer, a platform layer, a service layer and a display layer, wherein the data layer internally comprises data acquisition, data processing, data loading, data issuing, ETL data extraction, etiological and monitoring information data, epidemiological analysis data, laboratory data, environment and serum monitoring data and sequence data. According to the invention, the antigen variation condition of a new virus and the epidemic condition of the new virus in a group are predicted through a vaccine strain recommendation model; a series of potential vaccine strains are recommended in real time; a virus harmfulness prediction model is used for predicting the potential hazards of thevirus under an epidemic condition; a calculation model of the binding capacity between HA protein of a toxic strain and sialic acid receptors of different hosts is established through a toxic strain receptor affinity prediction model; and the emergency disposal and comprehensive prevention and control capacity of the new outburst epidemic virus is enhanced through the etiological and monitoring information data and the epidemiological analysis data.

The present invention relates to a novel MDCK-derived cell line capable of being suspension-cultured in a protein-free medium and a method for proliferating a virus using the MDCK-derived cell line to produce a vaccine. The novel MDCK-derived cell line exhibits high and uniform productivity for various viruses, while causing less viral antigenic variations with low tumorigenicity, and thus can be useful in producing viruses used for vaccines.

The invention discloses an antigen polypeptide for preparing a porcine circovirus synthetic peptide vaccine, a polypeptide composition and a vaccine. The antigen polypeptide is a polypeptide with sequence 1 or sequence 2. The vaccine comprises the polypeptide or the polypeptide composition. The porcine circovirus synthetic peptide vaccine provided by the invention has good immune potency, and does not induce fever, swelling and other problems like traditional vaccines. Therefore, the vaccine of the invention can effectively deal with the antigenic variation of porcine circovirus, has good biosafety, is easy for large-scale synthesis, and has good application prospects. The invention also provides a preparation method and pharmaceutical applications of the polypeptide and the polypeptide vaccine.

The invention provides an adaption method of influenza virus vaccine strains on Vero cells. The influenza virus vaccine strains are rapidly adapted on the Vero cells; and various effective virus adaption methods are established, so that influenza virus seeds can be adapted on the Vero cells, and virus progenies used as vaccines are produced under the condition of minimizing virus surface antigen variation caused by virus adaptation selection. The hemagglutination titer of the virus seeds prepared by vaccine strains adapted by the method is more than or equal to 160, and meets the requirementsof three parts of the Chinese pharmacopoeia, 2010 edition.

The invention provides a method and a reagent for identifying an antibody combined with a mutant antigen. According to the method, the antibody combined with the mutant antigen can be rapidly and accurately identified, the detection timeliness is ensured, the detection efficiency is high, the cost is low, and the method has important significance for guiding prevention and control of the current-stage new crown epidemic situation with epidemic situation outbreak and rapid antigen variation.

The invention provides an Asia I synthetic peptide vaccine of a foot and mouth disease, in particular to a polypeptide or a polypeptide polymer thereof for the Asia I synthetic peptide vaccine of the foot and mouth disease, the vaccine containing the polypeptide or the polypeptide polymer thereof, and a preparation method of both, wherein, the amino acid sequence of the polypeptide is shown as SEQ ID NO:1. In the invention, variation situation of main antigen sites of the foot and mouth disease is researched by determining a sequence of an epidemic strain of the foot and mouth disease, and meanwhile analysis prediction of the antigen sites of the foot and mouth disease is performed followed by chemical synthesis on possible peptide segments of the antigen sites combined with a computer auxiliary method; and candidate polypeptide antigens are screened through a large quantity of animal experiments to finally obtain the polypeptide antigens with high immune reaction level which can protect well an animal from being attacked by the epidemic strain of the foot and mouth disease. The vaccine prepared from the polypeptide antigens has the advantages of no biological safety problem, easylarge-scale synthesis, good application prospect and good ability of effectively dealing with antigen variation of foot and mouth disease virus.

The invention discloses a hybridoma cell strain which secretes a monoclonal antibody against rabies virus M protein and an application thereof, belonging to the field of biotechnology. The hybridoma cell line is classified and named as hybridoma cell line 4A1, which was deposited in the China Type Culture Collection on April 1, 2019, at the address: Wuhan, Wuhan, China, and the deposit number is CCTCC NO: C201947. The monoclonal antibody prepared by the hybridoma cell line has high titer, good specificity and excellent biological characteristics; it has identified the fine antigen variant epitope that recognizes the RABV M protein and can be used to distinguish the vaccine Flury strain from other RABV strains ; It is applied to the preparation of a kit for detecting rabies virus RABV, which can detect RABV infection and differential diagnosis vaccine Flury strain and other RABV strains.

The invention provides polypeptide for preparing a cattle foot-and-mouth disease ASIAI type peptide vaccine. The polypeptide comprises an amino acid sequence shown as SEQIDNO.1 and the peptide vaccine comprising the polypeptide. The cattle foot-and-mouth disease ASIAI type combined peptide vaccine is good in immune potency and does not cause the problems of a fever, swelling and the like caused by a tradition vaccine. Thus, the polypeptide for preparing the cattle foot-and-mouth disease ASIAI type peptide vaccine can effectively solve the problems of antigen and variation and nonexistence of bio-security of an existing foot-and-mouth disease virus, can be easily synthesized massively and has a good application prospect. The invention further provides a preparing method and use of the polypeptide and the peptide vaccine.

The invention provides polypeptide used for preparing O type peptide vaccine of cattle foot-and-mouth disease. The polypeptide comprises an amino acid sequence presented by SEQ ID NO.1 and the peptide vaccine containing the polypeptide. The O type synthetic peptide vaccine of cattle foot-and-mouth disease provided by the invention has excellent immune efficacy, and cannot cause the problems of fever, swelling and the like existing in traditional vaccines, so that the vaccine can effectively respond to antigenic variation of current foot-and-mouth disease virus, prevents biosecurity problems, is easy to synthesize in a large scale, and has an excellent application prospect. The invention further provides preparation methods and pharmaceutical applications of the polypeptide and the peptide vaccine.

The present invention provides modified protozoan parasites comprising at least two variable surface proteins (VSPs) simultaneously expressed on their surface. The modified protozoan also expresses all species of variable surface proteins simultaneously. Protozoa show reduced expression of Dicer and / or RNA-dependent RNA polymerase (RdRP), wherein the RdRP gene and / or Dicer gene is silenced. The protozoan may be any protozoan that exhibits a mechanism of antigenic variation.

The invention provides antigen peptides for preparing a porcine circovirus synthetic peptide vaccine as well as an application. The antigen peptides are peptides shown in the sequence 2, the sequence3 or the sequence 4. The porcine circovirus synthetic peptide vaccine has excellent immune efficiency, and the existing problems of fever, inflammation and the like of traditional vaccines cannot be caused. As a result, the vaccine can effectively cope with present antigen variation of porcine circovirus and no biosecurity, is prone to synthesis on a large scale, and has bright application prospects. The invention also provides a preparation method of the peptides and the peptide vaccine as well as a pharmaceutical application thereof.

The invention discloses an antigen polypeptide for preparing a porcine circovirus synthetic peptide vaccine, a polypeptide composition and a vaccine. The antigen polypeptide is a polypeptide with sequence 1 or sequence 2. The vaccine comprises the polypeptide or the polypeptide composition. The porcine circovirus synthetic peptide vaccine provided by the invention has good immune potency, and does not induce fever, swelling and other problems like traditional vaccines. Therefore, the vaccine of the invention can effectively deal with the antigenic variation of porcine circovirus, has good biosafety, is easy for large-scale synthesis, and has good application prospects. The invention also provides a preparation method and pharmaceutical applications of the polypeptide and the polypeptide vaccine.

The invention provides an antigen polypeptide composition and vaccine for preparing a cow foot-and-mouth disease O-type and A-type divalent synthetic peptide vaccine. The antigen peptide composition comprises polypeptides as shown in sequence 1 and sequence 2. The vaccine in the invention comprises the polypeptide composition. The cow foot-and-mouth disease O-type and A-type divalent synthetic peptide vaccine provided by the invention has good immunological efficiency, and the antigen of the vaccine is chemically synthetic peptide and does not contain foot-and-mouth disease viral nucleic acid particles, and the safety is high. Therefore, the vaccine in the invention can effectively solve antigenic variation of current foot-and-mouth disease virus, the biological safety is low, and the vaccine is easy for large-scale synthesis and has a good application prospect. The invention also provides a preparation method and pharmacy application of polypeptide and peptide vaccines.

The invention provides a polypeptide used for preparing bovine foot and mouth disease type O peptide vaccine. The polypeptide comprises an amino acid sequence represented by SEQ ID NO.1. The invention also provides a peptide vaccine comprising the polypeptide. The provided bovine foot and mouth disease type O synthetic peptide vaccine has good immunization effect, and does not cause problems such as fever and red swelling of traditional vaccines. Therefore, the vaccine provided by the invention is effective against current antigenic variations of foot and mouth disease, and has no biological safety problem. The vaccine is suitable for large-scale synthesis, and has good application prospect. The invention also provides preparation methods of the polypeptide and the peptide vaccine, and a pharmaceutical application thereof.

The invention relates to the field of animal virology, and provides separation identification and purification methods, biological characteristics and applications in biology of a recombinant fowl H9N2 avian influenza virus strain with preservation number being CCTCC NO:V200812; the differences between the virus and other separation strains are explained in term of molecular level; and the virus strain is proved to be capable of being used as candidate strain of avian influenza vaccines and as antigen of H9 subtype AIV hemoagglutination and hemoagglutination inhibition test (HA-HI). The strain has significance in knowing the molecular evolution and antigenic variation of fowl H9N2 avian influenza virus in China.

The invention discloses an antigen polypeptide for preparing a canine parvovirus synthetic peptide vaccine, a polypeptide composition and a vaccine. The antigen polypeptide is a polypeptide shown as asequence 1 or a sequence 2. The vaccine comprises the polypeptide or the polypeptide composition. The vaccine prepared from the polypeptide is capable of effectively coping with antigen variation ofthe canine parvovirus, is free of the problem of safety and easy to synthesize in large scale, and has good application prospects.

The invention discloses an antigen polypeptide for preparing a canine parvovirus synthetic peptide vaccine, a polypeptide composition and a vaccine. The antigen polypeptide is a polypeptide shown as asequence 1 or a sequence 2. The vaccine comprises the polypeptide or the polypeptide composition. The vaccine prepared from the polypeptide is capable of effectively coping with antigen variation ofthe canine parvovirus, is free of the problem of safety and easy to synthesize in large scale, and has good application prospects.